A concentrated aglycone isoflavone preparation (GCP) that demonstrates potent anti-prostate cancer activity in vitro and in vivo

Clinical Cancer Research

Volumn 10, Issue 15, 2004, Pages 5282-5292

  Bemis, Debra L ^a   Capodice, Jillian L ^a   Desai, Manisha ^b   Buityan, Ralph ^a   Katz, Aaron E ^a  

^a Columbia University Medical Center ^*  (United States)

^b NewYork Presbyterian Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGLYCONE ISOFLAVONE DERIVATIVE; GCP; GENISTEIN; GENISTEIN COMBINED POLYSACCHARIDE; ISOFLAVONE DERIVATIVE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN KINASE B; PROTEIN P21; PROTEIN P27; PROTEIN P53; REGULATOR PROTEIN; UNCLASSIFIED DRUG;

ANDROGEN METABOLISM; ANTINEOPLASTIC ACTIVITY; ARTICLE; BASIDIOMYCETES; CANCER INHIBITION; CANCER PREVENTION; CELL GROWTH; CHEMOPROPHYLAXIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG EFFICACY; DRUG POTENCY; DRUG SYNTHESIS; FERMENTATION TECHNIQUE; FLUORESCENCE ACTIVATED CELL SORTING; GLYCOSYLATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; PRIORITY JOURNAL; PROSTATE CANCER; SOYBEAN; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; WESTERN BLOTTING;

ANIMALS; ANTICARCINOGENIC AGENTS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DOSE-RESPONSE RELATIONSHIP, DRUG; FLOW CYTOMETRY; GENISTEIN; GLYCOSYLATION; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; PHOSPHORYLATION; POLY(ADP-RIBOSE) POLYMERASES; POLYSACCHARIDES; PROSTATIC NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; TIME FACTORS; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 4143083764     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-03-0828     Document Type: Article

References (47)

1. American Cancer Society. Cancer facts and figures, 2003. Atlanta, GA: American Cancer Society; 2003.
2. Petrylak DP. Chemotherapy for androgen-independent prostate cancer. Semin Urol Oncol 2002;20:31-35.
3. McClure MW. An overview of holistic medicine and complementary and alternative medicine for the prevention and treatment of BPH, prostatitis, and prostate cancer. World J Urol 2002;20:273-84.
4. Steenkamp V. Phytomedicines for the prostate. Fitoterapia 2003;74:545-52.
5. Jacobson JS, Chetty AP. Complementary and alternative medicine in prostate cancer. Curr Oncol Rep 2001;3:448-52.
6. Peehl DM, Krishnan AV, Feldman D. Pathways mediating the growth-inhibitory actions of vitamin D in prostate cancer. J Nutr 2003;133:2461S-9S.
7. Duffield-Lillico AJ, Dalkin BL, Reid ME, et al. Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. BJU Int 2003;91:608-12.
8. Lee MM, Gomez SL, Chang JS, et al. Soy and isoflavone consumption in relation to prostate cancer risk in China. Cancer Epidemiol Biomark Prev 2003;12:665-8.
9. Hsing AW, Chokkalingam AP, Gao YT, et al. Allium vegetables and risk of prostate cancer: a population-based study. J Natl Cancer Inst (Bethesda) 2002;94:1648-51.
10. Jatoi A, Ellison N, Burch PA, et al. A Phase II trial of green tea in the treatment of patients with androgen independent metastatic prostate carcinoma. Cancer (Phila) 2003;97:1442-6.
11. Hebert JR Hurley TG, Olendzki BC, et al. Nutritional and socioeconomic factors in relation to prostate cancer mortality: a cross-national study. J Natl Cancer Inst (Bethesda) 1998;90:1637-47.
12. Adlercreutz H. Epidemiology of phytoestrogens. Baillieres Clin Endocrinol Metab 1998;12:605-23.
13. Adlercreutz H, Honjo H, Higashi A, et al. Urinary excretion of lignans and isoflavonoid phytoestrogens in Japanese men and women consuming a traditional Japanese diet. Am J Clin Nutr 1991;54:1093-100.
14. Morton MS, Chan PS, Cheng C, et al. Lignans and isoflavonoids in plasma and prostatic fluid in men: samples from Portugal, Hong Kong, and the United Kingdom. Prostate 1997;32:122-8.
15. Shimizu H, Ross RK, Bernstein L, et al. Cancers of the prostate and breast among Japanese and white immigrants in Los Angeles County. Br J Cancer 1991;63:963-6.
16. Yu L, Blackburn GL, Zhou JR. Genistein and daidzein downregulate prostate androgen-regulated transcript-1 (PART-1) gene expression induced by dihydrotestosterone in human prostate LNCaP cancer cells. J Nutr 2003;133:389-92.
17. Akiyama T, Ishida J, Nakagawa S, et al. Genistein, a specific inhibitor of tyrosine-specific protein kinases. J Biol Chem 1987;262:5592-5.
18. Kumi-Diaka J, Butler A. Caspase-3 protease activation during the process of genistein-induced apoptosis in TM4 testicular cells. Biol Cell 2000;92:115-24.
19. Constantinou A, Mehta R, Runyan C, et al. Flavonoids as DNA topoisomerase antagonists and poisons: structure-activity relationships. J Nat Prod 1995;58:217-25.
20. Fotsis T, Pepper M, Adlercreutz H, et al. Genistein, a dietary-derived inhibitor of in vitro angiogenesis. Proc Natl Acad Sci USA 1993;90:2690-4.
21. 1 cell-cycle arrest in human prostate cancer cells. Mol Carcinog 2000;29:92-102.
22. WAF1, downregulation of cyclin B, and induction of apoptosis in prostate cancer cells. Nutr Cancer 1998;32:123-31.
23. Jarred RA, Keikha M, Dowling C, et al. Induction of apoptosis in low to moderate-grade human prostate carcinoma by red clover-derived dietary isoflavones. Cancer Epidemiol Biomark Prev 2002;11:1689-96.
24. Setchell KD, Brown NM, Zimmer-Nechemias L, et al. Evidence for lack of absorption of soy isoflavone glycosides in humans, supporting the crucial role of intestinal metabolism for bioavailability. Am J Clin Nutr 2002;76:447-53.
25. Miura T, Yuan L, Sun B, et al. Isoflavone aglycon produced by culture of soybean extracts with basidiomycetes and its anti-angiogenic activity. Biosci Biotechnol Biochem 2002;66:2626-31.
26. Chen MW, Vacherot F, De La Taille, A, et al. The emergence of protocadherin-PC expression during the acquisition of apoptosis-resistance by prostate cancer cells. Oncogene 2002;21:7861-71.
27. Raffo AJ, Perlman H, Chen MW, et al. Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res 1995;55:4438-45.
28. Taguchi A, Blood DC, del Toro G, et al. Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature (Lond) 2000;405:354-60.
29. Nakamura N, Ramaswamy S, Vazquez F, et al. Forkhead transcription factors are critical effectors of cell death and cell cycle arrest downstream of PTEN. Mol Cell Biol 2000;20:8969-82.
30. Maggiolini M, Bonofiglio D, Marsico S, et al. Estrogen receptor alpha mediates the proliferative but not the cytotoxic dose-dependent effects of two major phytoestrogens on human breast cancer cells. Mol Pharmacol 2001;60:595-602.
31. Fritz WA, Wang J, Eltoum IE, Lamartiniere CA. Dietary genistein down-regulates androgen and estrogen receptor expression in the rat prostate. Mol Cell Endocrinol 2002;186:89-99.
32. Davis JN, Kucuk O, Sarkar FH. Genistein inhibits NF-kappa B activation in prostate cancer cells. Nutr Cancer 1999;35:167-74.
33. Wang S, DeGroff VL, Clinton SK. Tomato and soy polyphenols reduce insulin-like growth factor-1-stimulated rat prostate cancer cell proliferation and apoptotic resistance in vitro via inhibition of intracellular signaling pathways involving tyrosine kinase. J Nutr 2003;133:2367-76.
34. Knowles LM, Zigrossi DA, Tauber RA, Hightower C, Milner JA. Flavonoids suppress androgen-independent human prostate tumor proliferation. Nutr Cancer 2000;38:116-22.
35. Kyle E, Neckers L, Takimoto C, Curt G, Bergan R. Genistein-induced apoptosis of prostate cancer cells is preceded by a specific decrease in focal adhesion kinase activity. Mol Pharmacol 1997;51:193-200.
36. Parker WB, Cheng YC. Metabolism and mechanism of action of 5-fluorouracil. Pharmacol Ther 1990;48:381-95.
37. Piazza GA, Rahm AK, Finn TS, et al. Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest, and p53 induction. Cancer Res 1997;57:2452-9.
38. Evans BA, Griffiths K, Morton MS. Inhibition of 5 alpha-reductase in genital skin fibroblasts and prostate tissue by dietary lignans and isoflavonoids. J Endocrinol 1995;147:295-302.
39. Yang CC, Lin HP, Chen CS, et al. Bcl-xL mediates a survival mechanism independent of the phosphoinositide 3-kinase/Akt pathway in prostate cancer cells. J Biol Chem 2003;278:25872-8.
40. Ghafar MA, Golliday E, Bingham J, et al. Regression of prostate cancer following administration of Genistein Combined Polysaccharide (GCP), a nutritional supplement: a case report. J Altern Complement Med 2002;8:493-7.
41. Ngai PH, Ng TB. Lentin, a novel and potent antifungal protein from shitake mushroom with inhibitory effects on activity of human immunodeficiency virus-1 reverse transcriptase and proliferation of leukemia cells. Life Sci 2003;73:3363-74.
42. Abraham WR. Bioactive sesquiterpenes produced by fungi: are they useful for humans as well? Curr Med Chem 2001;8:583-606.
43. Shiao MS. Natural products of the medicinal fungus Ganoderma lucidum: occurrence, biological activities, and pharmacological functions. Chem Rec 2003;3:172-80.
44. Bao X, Fang J, Li X. Structural characterization and immunomodulating activity of a complex glucan from spores of Ganoderma lucidum. Biosci Biotechnol Biochem 2001;65:2384-91.
45. Ning J, Zhang W, Yi Y, et al. Synthesis of beta-(1→6)-branched beta-(1→3) glucohexaose and its analogues containing an alpha-(1→3) linked bond with antitumor activity. Bioorg Med Chem 2003;11:2193-203.
46. Wasser SP. Medicinal mushrooms as a source of antitumor and immunomodulating polysaccharides. Appl Microbiol Biotechnol 2002;60:258-74.
47. Jakucs E, Racz I, Lasztity D. Some characteristics and partial purification of the Ganoderma lucidum cellulose system. Acta Microbiol Immunol Hung 1994;41:23-31.